Registration of Additional Securities (up to 20%) (s-1mef)
August 04 2022 - 9:19AM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on August 4, 2022
Registration No. 333-
UNITED STATES
Securities and Exchange Commission
Washington, D.C. 20549
Form S-1
Registration Statement Under The Securities Act
of 1933
Applied DNA Sciences, Inc.
(Exact name of Registrant as specified in its charter)
Delaware |
|
7380 |
|
59-2262718 |
(State or other jurisdiction
of incorporation or organization) |
|
(Primary Standard Industrial
Classification Code Number) |
|
(I.R.S. Employer
Identification No.) |
50 Health Sciences Drive
Stony Brook, New York 11790
(631) 240-8800
(Address, including zip code, and telephone number,
including area code, of Registrant’s principal executive offices)
James A. Hayward, Ph.D., Sc.D.
Chairman, Chief Executive Officer and President
Applied DNA Sciences, Inc.
50 Health Sciences Drive
Stony Brook, New York 11790
(631) 240-8801
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
COPIES TO:
Merrill M. Kraines, Esq.
Todd Kornfeld
McDermott Will & Emery LLP
One Vanderbilt Avenue
New York, NY 10017-3852
212-547-5616
|
|
Robert F. Charron
Ellenoff Grossman & Schole LLP
1345 Avenue of the Americas
New York, NY 10105
212-370-1300
|
Approximate date of commencement of proposed sale to the public:
As soon as practicable after this Registration Statement becomes effective.
If any of the securities being
registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following
box. x
If this Form is filed to register
additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering x 333-266223
If this Form is a post-effective
amendment filed pursuant to Rule 462(c) under the Securities Act of 1933, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering ¨
If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. ¨
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting
company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
|
¨ |
|
Accelerated filer |
|
¨ |
Non-accelerated filer |
|
x |
|
Smaller reporting company |
|
x |
Emerging Growth Company |
|
¨ |
|
|
|
|
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided in Section 7(a)(2)(B) of the Securities Act. ¨
The Registration Statement shall become effective upon filing with
the Securities and Exchange Commission in accordance with Rule 462(b) under the Securities Act of 1933, as amended.
EXPLANATORY NOTE
Applied DNA Sciences, Inc., a Delaware corporation
(the “Company”), is filing this registration statement with the Securities and Exchange Commission pursuant to Rule 462(b)
under the Securities Act of 1933, as amended. This registration statement relates to the public offering of securities contemplated by
the registration statement on Form S-1, as amended (File No. 333-266223) (the “Prior Registration Statement”), which
the Securities and Exchange Commission declared effective on August 4, 2022.
The Company is filing this registration statement
for the sole purpose of registering the following additional securities of the Company: (i) shares of the Company’s common stock,
par value $0.001 per share and accompanying Series A warrants to purchase shares of common stock (“Series A Warrants”) and
accompanying Series B warrants to purchase shares of common stock (“Series B Warrants”; and, together with the Series A Warrants,
the “Series Warrants”); (ii) the Company’s pre-funded warrants to purchase shares of common stock and accompanying Series
Warrants; and (iii) shares of common stock underlying the pre-funded warrants and Series Warrants.
The proposed maximum aggregate offering price
of the common stock and accompanying Series Warrants will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded
warrants and accompanying Series Warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded
warrants and accompanying Series Warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering
price of any common stock and accompanying Series Warrants issued in the offering.
The additional securities that are being registered
for sale have a proposed maximum offering price not to exceed $6,000,000 and are in an amount and at a price that together represent no
more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee table contained in the Prior Registration
Statement. The information set forth in the Prior Registration Statement, and all exhibits to the Prior Registration Statement, are hereby
incorporated by reference into this registration statement.
The required opinion and
consents are listed on the exhibit index attached hereto and filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, as amended, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the Town of Stony Brook, State of New York, on August 4, 2022.
|
APPLIED DNA SCIENCES, INC. |
|
|
|
|
By: |
/s/ James A. Hayward |
|
|
James A. Hayward |
|
|
President and Chief Executive Officer |
Pursuant to the requirements of the Securities
Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date |
|
|
|
/s/ James A. Hayward |
President, Chairman of the Board of Directors and Director |
August 4, 2022 |
James A. Hayward |
Chief Executive Officer (Principal Executive Officer) |
|
|
|
|
/s/ Beth Jantzen |
Chief Financial Officer |
August 4, 2022 |
Beth M. Jantzen |
(Principal Financial Officer and Principal Accounting Officer) |
|
|
|
|
/s/ * |
Director |
August 4, 2022 |
John Bitzer, III |
|
|
|
|
|
/s/ * |
Director |
August 4, 2022 |
Robert Catell |
|
|
|
|
|
/s/ * |
Director |
August 4, 2022 |
Joseph D. Ceccoli |
|
|
|
|
|
/s/ * |
Director |
August 4, 2022 |
Scott L. Anchin |
|
|
|
|
|
/s/ * |
Director |
August 4, 2022 |
Yacov A. Shamash |
|
|
|
|
|
/s/ * |
Director |
August 4, 2022 |
Sanford R. Simon |
|
|
|
|
|
/s/ * |
Director |
August 4, 2022 |
Elizabeth M. Schmalz |
|
|
*By: |
/s/ Beth Jantzen |
|
|
|
Beth M. Jantzen |
|
|
|
Attorney-in-Fact |
|
|
EXHIBIT INDEX
* |
Filed herewith. |
** |
Previously filed. |
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024